Camonsertib

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameCamonsertib
Drug Alias NameRP-3500RG6526
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsSolid tumoursParanasal Sinus DiseasesNeoplasm Metastasis +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesRepare Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche LtdNational Cancer InstituteRepare Therapeutics Inc
Inactive CompaniesUtah State UniversityRoche (China) Holding Ltd
Active IndicationsSolid tumoursParanasal Sinus DiseasesNeoplasm Metastasis +[11] 
Inactive IndicationsLeukemia, Lymphocytic, Chronic, B-CellNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A